Examining the True Prevalence of Hypercortisolism and Its Impact on Managing Resistant Diabetes : Episode 5
Coexisting Cardiometabolic Conditions and Hypercortisolism
Medical experts discuss the implications of finding hypercortisolism in one-third of patients on three or more hypertension medications, the linkage between hypercortisolism and type 2 diabetes as presented in the ‘Pathologic Mechanisms of Hypercortisolism in Type 2 Diabetes’ session, and how hypercortisolism affects diabetes management, including the importance of addressing it and its consequences for patients with difficult-to-control diabetes.
EP: 1.Overview of the CATALYST Study for Hypercortisolism
EP: 2.Defining Difficult to Control Diabetes
EP: 3.CATALYST Trial Study Design
EP: 4.True Prevalence of Hypercortisolism
Now Viewing
EP: 5.Coexisting Cardiometabolic Conditions and Hypercortisolism
EP: 6.Engaging Primary Care Clinicians in Screening for Hypercortisolism
EP: 7.Spectrum of Hypercortisolism Presentations
EP: 8.Mifeprestone for Treatment of Hypercortisolism
EP: 9.Reconsidering Standard of Care for Hypercortisolism
Video content above is prompted by the following:
How do you interpret the finding that one-third of patients on three or more hypertension medications also had hypercortisolism?
- You presented the ‘Pathologic Mechanisms of Hypercortisolism in Type 2 Diabetes’ at the last ADA scientific session. Can you briefly explain the linkage between hypercortisolism and diabetes?
- How does hypercortisolism physiologically impact the management of T2D?
- Why is it important to address hypercortisolism? What are the consequences of untreated hypercortisolism in patients with diabetes?
- What are the clinical implications of this data? How does it inform or change the way we manage patients with difficult-to-control diabetes?
Recent Videos
